Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Exicure, Inc. (XCUR)

1.0100 +0.0416 (+4.30%)
At close: October 30 at 4:00:00 PM EDT
0.9843 -0.0257 (-2.54%)
Pre-Market: 4:00:22 AM EST
Chart Range Bar
Loading chart for XCUR
  • Previous Close 0.9684
  • Open 0.9438
  • Bid 1.7800 x 100
  • Ask 1.7100 x 200
  • Day's Range 0.9438 - 1.0600
  • 52 Week Range 0.8750 - 9.4800
  • Volume 29,566
  • Avg. Volume 45,456
  • Market Cap (intraday) 6.611M
  • Beta (5Y Monthly) 3.74
  • PE Ratio (TTM) --
  • EPS (TTM) -1.3100
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.

www.exicuretx.com

1

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

XCUR
81.37%
S&P 500 (^GSPC)
10.73%

1-Year Return

XCUR
77.25%
S&P 500 (^GSPC)
11.11%

3-Year Return

XCUR
67.42%
S&P 500 (^GSPC)
81.91%

5-Year Return

XCUR
99.40%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY22
Revenue 2.47M
Earnings --
Profit Margin 0.00%

Q3

FY21

Q4

FY21

Q1

FY22

Q2

FY22

-20M
-15M
-10M
-5M
0
0.0%
200.0%
400.0%
600.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -30.32%

  • Return on Equity (ttm)

    -168.37%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -8.28M

  • Diluted EPS (ttm)

    -1.3100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.72M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -3.62M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: